Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Foye

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Cancer Letters|June 26, 2016
An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancerGayatri Premasekharan, Elizabeth Gilbert, Ross A Okimoto, et al.
Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.
Molecular Cancer Research : MCR|March 29, 2019
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass HeterogeneityRahul R Aggarwal, David A Quigley, Jiaoti Huang, et al.
Prostate Cancer and Prostatic Diseases|March 31, 2025
Racial variation in the advanced prostate cancer genomeEmily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null DiseaseNing Zhao, Shalini Chopra, Kai Trepka, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
Urologic Oncology|July 7, 2020
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancerDaniel H Kwon, Li Zhang, David A Quigley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Cancer Letters|June 26, 2016
An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancerGayatri Premasekharan, Elizabeth Gilbert, Ross A Okimoto, et al.
Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.
Molecular Cancer Research : MCR|March 29, 2019
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass HeterogeneityRahul R Aggarwal, David A Quigley, Jiaoti Huang, et al.
Prostate Cancer and Prostatic Diseases|March 31, 2025
Racial variation in the advanced prostate cancer genomeEmily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null DiseaseNing Zhao, Shalini Chopra, Kai Trepka, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
Urologic Oncology|July 7, 2020
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancerDaniel H Kwon, Li Zhang, David A Quigley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Pageof 4